Site Manager & Senior Clinical Research Coordinator
Mayelin Perez, M.Sc., CRC
Site manager, start-up specialist, and senior clinical research coordinator with a decade of site leadership and coordination across more than 60 industry-sponsored trials in cardiometabolic, respiratory, gastrointestinal, CNS, and pediatric research.
Profile
Mayelin Perez leads site operations at Salud Clinical Services, overseeing study start-up, contracts, staff training, and day-to-day coordination. She spent a decade at Columbus Clinical Services in Miami as site manager, contract and business director, and lead senior clinical research coordinator.
Her earlier career includes a doctorate in dental medicine, an orthodontics specialty, and a master's degree in natural and bioenergetic medicine, plus Florida licensure as a registered dental hygienist.
- Profile
- Site operations and study start-up
- At Salud since
- 2025
- Languages
- English and Spanish
Education and training
- Local Anesthesia Administration Certification — Florida Registry of Health Care Professionals, Miami, 2019
- Registered Dental Hygienist — Florida Registry of Health Care Professionals, Miami, 2018
- Registered Dental Assistant — Florida Registry of Health Care Professionals, Miami, 2015
- M.Sc. Natural and Bioenergetic Medicine — Higher Institute of Medical Sciences "Carlos J. Finlay", Camagüey, Cuba, 2009
- Specialist Degree in Orthodontics — Higher Institute of Medical Sciences "Carlos J. Finlay", Camagüey, Cuba, 2003
- Doctor of Dental Medicine — Higher Institute of Medical Sciences "Carlos J. Finlay", Camagüey, Cuba, 1997
Licenses and certifications
- Clinical Research Coordinator (CRC)
- Registered Dental Hygienist, Florida
Professional experience
- Salud Clinical Services, Lehigh Acres — Site Manager / Start-Up Specialist / Senior CRC — 2025–Present
- Columbus Clinical Services, Miami — Site Manager / Contract and Business Director / Lead Senior CRC — 2015–2025
- Dental American Group, Miami — Dental Hygienist — 2018–2021
- Educational Clinic Tula Aguilera, Camagüey, Cuba — Orthodontist — 2003–2015
Clinical research experience
| Study focus | Phase | Sponsor | Years |
|---|---|---|---|
| Hypercholesterolemia and heterozygous familial hypercholesterolemia programs | Phase 3 | Pfizer | 2015–2016 |
| Ulcerative colitis and chronic idiopathic constipation | Phase 1b/3 | Synergy | 2015–2016 |
| Moderate to severe COPD, including high-eosinophil population | Phase 3 | AstraZeneca / PEARL Therapeutics | 2015–2016 |
| Asthma in adults and adolescents | Phase 3 | AstraZeneca | 2017–2019 |
| Chronic heart failure with reduced ejection fraction | Phase 3 | Amgen | 2017–2019 |
| Type 2 diabetes mellitus in children and adolescents | Phase 3 | Janssen | 2018–2019 |
| ASCVD with elevated LDL-C (ORION-10) | Phase 3 | The Medicines Company | 2018–2019 |
| Early Alzheimer's disease and mild cognitive impairment | Phase 1/2 | Acumen Pharmaceuticals and others | 2019–2023 |
| Schizophrenia maintenance and prospective adult treatment | Phase 2/3 | Teva, Otsuka, Cerevel | 2019–2025 |
| Moderate to severe ulcerative colitis (LUCENT 1/2, ASTRO) | Phase 3 | Eli Lilly, Janssen | 2019–2023 |
| Helicobacter pylori infection and erosive esophagitis | Phase 3 | Phathom Pharmaceuticals | 2019–2022 |
| COVID-19 prevention (PROVENT, STORM CHASER) and treatment | Phase 2/3 | AstraZeneca, Revive Therapeutics, SyneuRx | 2020–2022 |
| Pediatric migraine (ages 6–11) | Phase 4 | Supernus Pharmaceuticals | 2020–2022 |
| Severe asthma (NIMBLE, SWIFT) | Phase 3 | GSK | 2021–2023 |
| Pediatric schizophrenia, bipolar I disorder, and autism spectrum disorder | Phase 3 | AbbVie / Allergan, Intra-Cellular Therapies | 2021–2025 |
| Severe hypertriglyceridemia | Phase 3 | Ionis Pharmaceuticals | 2022–2024 |
| Osteoarthritis pain of the knee | Phase 3 | Biosplice Therapeutics | 2022–2024 |
| Moderate to severe atopic dermatitis | Phase 2 | AnaptysBio | 2022–2024 |
| Major adverse cardiovascular events in high-risk patients | Phase 3 | Merck | 2023–2025 |
| Primary prevention of ASCVD and elevated lipoprotein(a) | Phase 2/3 | Novartis, Amgen | 2023–2025 |
| Moderate to very severe COPD (EMBARK, THESEUS) | Phase 2/3 | AstraZeneca, Sanofi | 2025–Present |
Frequently asked questions
Answers to questions we hear most often.
What is a Principal Investigator?
The Principal Investigator is the qualified clinician responsible for conducting the study at the site, protecting participant safety, and ensuring the protocol is followed.
Who will I see at my study visits?
Most visits are conducted by a clinical research coordinator, with the Principal Investigator or a sub-investigator involved in medical assessments and safety review.
Is the research staff trained in Good Clinical Practice?
Yes. GCP and protocol-specific training is completed and documented before staff are delegated study responsibilities.
Can I request a Spanish-speaking coordinator?
Yes. Our team is bilingual and visits can be conducted in English or Spanish.
Information on this website is provided for general educational purposes about clinical research and is not medical advice. Participation in any study is voluntary.